Distant recurrence-free survival of postmenopausal, oestrogen-receptor-positive breast cancer patients in relation to the genotype and adjuvant tamoxifen therapy

<p><b>Copyright information:</b></p><p>Taken from "Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients"</p><p>Breast Cancer Research 2005;7(3):R284-R290.</p><p>Published online 28 Jan 2005</p><p>PMCID:PMC1143572.</p><p>Copyright © 2005 Wegman et al., licensee BioMed Central Ltd.</p> Solid line, patients receiving tamoxifen (Tam+); dashed line, patients who did not receive tamoxifen (Tam-). Patients homozygous for the allele. The number of events for Tam+ and Tam- were 9 and 16, respectively. Patients homozygous or heterozygous for the allele (low-activity allele). The number of events for Tam+ and Tam- were 24 and 26, respectively